Haemonetics Corporation
HAE
Clasificación en acciones
#3272
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Precio por acción
$118.49
Última sincronización: 2026-10-16
Capitalización bursátil
$5.39B
Cambio (1 día)
-2.43%
Cambio (1 año)
135.75%
País
US
Comercio Haemonetics Corporation (HAE)
Categoría
Healthcare
Margen Operativo de Haemonetics Corporation (HAE)
Margen Operativo al October 2026 TTM: 18.18%
Según los informes financieros más recientes y el precio de las acciones de Haemonetics Corporation, el margen operativo actual (TTM) es 18.18%. Al final de 2024, el margen operativo era 12.60%.
Historial de Margen Operativo de Haemonetics Corporation desde 2000 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 18.18% | 11.53% |
| 2025 | 16.30% | 29.37% |
| 2024 | 12.60% | -5.62% |
| 2023 | 13.35% | 64.21% |
| 2022 | 8.13% | 22.07% |
| 2021 | 6.66% | -57.23% |
| 2020 | 15.57% | 80.42% |
| 2019 | 8.63% | 38.97% |
| 2018 | 6.21% | -383.56% |
| 2017 | -2.19% | -54.75% |
| 2016 | -4.84% | -208.76% |
| 2015 | 4.45% | -11.71% |
| 2014 | 5.04% | -20.38% |
| 2013 | 6.33% | -48.07% |
| 2012 | 12.19% | -25.40% |
| 2011 | 16.34% | 26.67% |
| 2010 | 12.90% | -9.85% |
| 2009 | 14.31% | 5.14% |
| 2008 | 13.61% | -2.51% |
| 2007 | 13.96% | -40.82% |
| 2006 | 23.59% | 50.93% |
| 2005 | 15.63% | 24.05% |
| 2004 | 12.60% | 13.31% |
| 2003 | 11.12% | -2.37% |
| 2002 | 11.39% | 149.23% |
| 2001 | 4.57% | -62.23% |
| 2000 | 12.10% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 17.03% | -99.06% |
US
|
|
| 17.86% | -99.02% |
IE
|
|
| 22.03% | -98.79% |
US
|
|
| 21.46% | -98.82% |
US
|
|
| 0.00% | - |
DE
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.